Utilization of MRD assessment in the clinical management of patients with multiple myeloma

Measurable residual disease (MRD) status is a known prognostic factor in multiple myeloma (MM). Offering the possibility to improve clinical trials, guide treatment decision-making and advance patient management, this is a field rich in potential.

Due to developments in MRD detection technologies and knowledge, MRD testing in MM is increasingly being integrated into clinical practice. Consequently, it is important that healthcare professionals understand the significance of MRD in terms of depth of response and treatment decision-making.

To explore the use of MRD monitoring as a tool in the management of MM patients, we covered the Adaptive Biotechnologies Symposium “Utilization of MRD assessment in the clinical management of patients with multiple myeloma” at the World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France on May 17th 2019.

Watch presentations from Kwee Yong and Maria-Victoria Mateos, followed by a discussion that also features Mohamad Mohty and Hervé Avet-Loiseau.

How can MRD guide MM treatment in
real-world practice?

Webcast presentations
Kwee Yong, PhD, FRCP, FRCPath
University College London, UK
Utilization of MRD assessment in real-world practice
Watch Part 1
A question of deferred
ASCT
Watch Part 2
MRD assessment in
clinical trials and clinical practice
Watch Part 3

What is the relevance of depth of response in newly diagnosed MM?

Webcast presentations
Maria-Victoria Mateos, MD, PhD
University Hospital of Salamanca, Spain
Why does depth of response matter in
NDMM?
Watch Part 1
Redefining the CR
criteria in MM:
cellular dissemination
Watch Part 2
Redefining the CR
criteria in MM:
cellular clonality
Watch Part 3

Discussion:
The value of MRD assessment in the clinical management of MM patients

Following Prof. Yong’s presentation, Discussants Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital, Paris, France, and Hervé Avet-Loiseau, MD, PhD, of the Cancer Research Center of Toulouse, Toulouse, France, facilitate a discussion on the relevance of differing sensitivities of MRD and whether the turnaround of MRD testing is significant.

Discussion:
The relevance of depth of response in newly diagnosed MM

Dr Mateos answers questions from Discussants Prof. Mohty and Prof. Avet-Loiseau on the data presented in her talk, including when to evaluate MRD in the treatment timeline, the next steps once MRD status is determined, and whether to assess MRD status in all patient groups.